Cardiol Therapeutics (CRDL) Corporate presentation summary

Pipeline and clinical programs

• Advancing CardiolRx™ for recurrent pericarditis (Phase III, >75% enrolled) and acute myocarditis (Phase II completed, data published).

• Developing CRD-38 for heart failure, currently in IND-enabling studies.

• CardiolRx™ modulates inflammasome pathway activation, targeting inflammation and fibrosis in heart disease.

• Phase II MAVERIC and ARCHER studies showed rapid pain reduction, inflammation control, and cardiac structural improvements.

• Phase III MAVERIC trial is a pivotal, multi-national, double-blind, placebo-controlled study targeting pericarditis recurrence.

Clinical results and efficacy

• MAVERIC Phase II: CardiolRx™ led to rapid, durable pain reduction and significant CRP decrease in recurrent pericarditis.

• 71% of patients experienced no recurrence during the extension period; events per year dropped from 5.8 to 0.9.

• ARCHER Phase II: CardiolRx™ significantly reduced LV mass and showed trends toward reduced extracellular and intracellular volumes in acute myocarditis.

• LV mass reduction with CardiolRx™ is comparable to leading heart failure and diabetes drugs.

• Both studies demonstrated CardiolRx™ was safe and well tolerated.

Market opportunity and strategic positioning

• CardiolRx™ targets a >$1B market in recurrent pericarditis, addressing ~40,000 patients in the US.

• Only one FDA-approved therapy exists for recurrent pericarditis, costing over $300k/year and used for multiple recurrences.

• CardiolRx™ offers an oral, non-immunosuppressant, disease-modifying alternative.

• Heart failure market is multi-billion dollar, with 8M US patients by 2030 and $30B in associated costs.

• No approved therapies specifically target inflammatory/fibrotic mechanisms in heart failure.